GlassScriptPhysician profile
Eric D Jennings
NPI 1154613974
$30,603.14
in general payments reported to CMS, 2019-2025
17 companies · $1,038 in 2025
The $1,038 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $381 · 2021: $311 · 2022: $5,025 · 2023: $17K · 2024: $6,512 · 2025: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Food and Beverage: $1,418 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,728.00 |
| Food and Beverage | $1,418.02 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,225.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Research LLC | $18,267.70 | 2022-2025 | Ngenuity |
| Alcon Vision LLC | $10,783.42 | 2019-2025 | Argos, Clareon |
| Abbvie INC. | $450.99 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $248.15 | 2019-2021 | |
| Glaukos Corporation | $136.76 | 2020-2025 | Idosetr, Istent Infinite |
| Rxsight INC | $122.68 | 2022-2023 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb Americas INC. | $122.67 | 2022 | |
| Allergan, INC. | $115.15 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $88.38 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $76.13 | 2020-2021 | |
| Oyster Point Pharma, INC. | $41.52 | 2022-2023 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $33.84 | 2020 | |
| Biotissue Holdings INC. | $32.07 | 2019-2022 | |
| Harrow Eye, LLC | $31.57 | 2024 | Vevye |
| Astellas Pharma US INC | $17.65 | 2025 | Izervay |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $17.25 | 2019 | |
| Dompe US, INC. | $17.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Jennings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.